(VIANEWS) – The NASDAQ ended the session with FibroGen (FGEN) jumping 10.53% to $1.89 on Tuesday while NASDAQ rose 1.54% to $16,265.64.
FibroGen’s last close was $1.71, 91.82% under its 52-week high of $20.90.
About FibroGen
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-2.92.
Revenue Growth
Year-on-year quarterly revenue growth declined by 21%, now sitting on 147.75M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
FibroGen’s EBITDA is 0.64.
Moving Average
FibroGen’s value is way higher than its 50-day moving average of $1.52 and way under its 200-day moving average of $3.01.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FibroGen’s stock is considered to be overbought (>=80).
More news about FibroGen (FGEN).
